The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.
Department of Medicine I, Markus-Krankenhaus, Wilhelm-Epstein-Str. 4, D-60431 Frankfurt/Main, Germany. axel.dignass@fdk.info
A
A
Dignass
G
G
Van Assche
J O
JO
Lindsay
M
M
Lémann
J
J
Söderholm
J F
JF
Colombel
S
S
Danese
A
A
D'Hoore
M
M
Gassull
F
F
Gomollón
D W
DW
Hommes
P
P
Michetti
C
C
O'Morain
T
T
Oresland
A
A
Windsor
E F
EF
Stange
S P L
SP
Travis
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002648:Child; D003251:Constriction, Pathologic / Q000601:surgery; D003424:Crohn Disease / Q000473:pathology / Q000628:therapy*; D004035:Diet Therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D007422:Intestines / Q000601:surgery; D008727:Methotrexate / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000305:Adrenal Cortex Hormones; D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011687:Purines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate